Journal
FUTURE ONCOLOGY
Volume 14, Issue 25, Pages 2663-2676Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2018-0210
Keywords
anthracycline; cardioprotective agents; clinical efficacy; dexrazoxane; doxorubicin; epirubicin; safety; second malignancy; survival
Categories
Funding
- Clinigen
Ask authors/readers for more resources
Dexrazoxane can prevent anthracycline-associated cardiotoxicity. However, in 2011, its use in children was contraindicated by the EMA over concerns of increased risk of infection, myelosuppression and second primary malignancies, and because its efficacy in children had not then been established. We review here the evidence published since 2011, which confirms that dexrazoxane is an effective cardioprotectant in children and adolescents, is not associated with an increased risk of second primary malignancies or excess early or late mortality and does not impair chemotherapy efficacy. Based on this evidence, the contraindication for children and adolescents requiring high doses of anthracyclines and at risk for cardiotoxicity was removed from the European labeling for dexrazoxane.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available